New drug cocktail aims to shrink tough lung cancers
NCT ID NCT07244926
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and bevacizumab—in 31 adults with advanced non-squamous lung cancer that has worsened after initial treatment. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive the drugs intravenously every two weeks until the cancer progresses or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab
What this could lead to
If successful, this combination could offer a new second-line treatment option for people with advanced non-squamous lung cancer who have no targetable gene changes.
What could go wrong
This is a small, early-phase trial with only 31 participants and no comparison group. The treatment may not work better than existing options and could cause side effects like infusion reactions or bleeding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.